Project Grant R44CA291369
Award Date
9/12/24
Completion Date
8/31/26
Dollars Obligated
$1.3M
Federal Agency
National Cancer Institute
Awardee
Exai Bio Inc. (URKGDDQ8AHJ5)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Regents of the University of California, San Francisco (UCSF) totaling $679,188. The grant will fund the development of liquid biopsy tests using artificial intelligence-assisted, morphology-based isolation of tumor cells from malignant effusions to evaluate known actionable breast cancer biomarkers and discover new predictive molecular and morphology-based...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,625,000.00 to Onc.ai, Inc. to develop and validate a radiomics-based multi-modal predictive model for metastatic non-small cell lung cancer patients treated with PD-1 immunotherapy. The key objectives are to: 1) Validate the predictive models in a multi-institutional prospective clinical study, 2) Evaluate the performance characteristics and...
The National Cancer Institute (NCI) awarded a $990,771 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Binary Genomics, Inc., a minority-owned for-profit organization located in Madison, CT. The project aims to build clinical data supporting the use of Binary Genomics' circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of lung cancer immunotherapies. The technology leverages epigenetic features to broadly detect ctDNA without...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...
This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
The National Cancer Institute (NCI) awarded PDX Pharmaceuticals Inc. a $321,304 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to advance the commercialization readiness of their nanoparticle-based immunotherapy for non-small cell lung cancer (NSCLC) treatment. The grant supports two key activities: 1) Pursuing international patent protection for PDX's core nanoparticle delivery platform (PDX-NP) and lead candidate ARAC-02 immunotherapy, and 2) Initiating...
The National Cancer Institute (NCI) awarded a 4-year, $554,653 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Institute for Systems Biology in Seattle, WA for the "RARECYTEFINDER" project. The goal of this project is to develop an advanced, label-free method for the unbiased identification and comprehensive molecular analysis of rare disseminated tumor cells (DTCs) present in liquid and tissue biopsy specimens across various solid tumor types. The...
The National Cancer Institute (NCI) awarded a $256,487 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research in New York, NY. The purpose of this 5-year grant is to develop multimodal predictive models that integrate real-world data from circulating tumor DNA (ctDNA) sequencing, radiomics, tumor registries, and tissue genomics to improve risk stratification and clinical management of non-small cell lung cancer (NSCLC). The...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $419,133.00 to the Massachusetts Institute of Technology (MIT) to develop an "ex vivo tumor biosensor" technology called AscitesPredict. The goal is to enable real-time evaluation of therapeutic sensitivities and cell identities from patient ascites (fluid accumulation) samples, which can be more readily obtained than traditional tumor biopsies. The...
The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $2,078,214 Project Grant to Precision Epigenomics Inc., a University of Arizona Cancer Center and Department of Pathology spin-out, to develop and validate the Sentinel-MPE liquid biopsy assay - a multi-cancer detection test that can identify over twenty different cancer types. The project aims to establish the diagnostic value of the Sentinel-MPE test and validate its use for cancer detection in...